PubRank

Rowan T Chlebowski

Author PubWeight™ 232.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006 12.44
2 The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007 12.23
3 Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006 12.09
4 Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006 8.73
5 Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011 8.19
6 Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013 7.19
7 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2004 6.59
8 Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006 6.51
9 Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008 4.42
10 Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011 3.85
11 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003 3.71
12 Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012 3.56
13 American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009 3.51
14 Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006 3.29
15 Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002 3.27
16 Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008 3.05
17 Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006 2.97
18 Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 2011 2.84
19 Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. J Womens Health (Larchmt) 2013 2.81
20 Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008 2.79
21 Frequency and predictive value of a mammographic recommendation for short-interval follow-up. J Natl Cancer Inst 2003 2.64
22 The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol 2003 2.64
23 Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003 2.49
24 Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst 2007 2.37
25 Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol 2014 2.25
26 Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005 2.16
27 Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007 2.01
28 Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med 2014 1.87
29 Influence of stressors on breast cancer incidence in the Women's Health Initiative. Health Psychol 2009 1.75
30 Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 2008 1.72
31 Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 2006 1.70
32 Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011 1.67
33 American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003 1.64
34 Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst 2013 1.60
35 Genetic variants in the MRPS30 region and postmenopausal breast cancer risk. Genome Med 2011 1.55
36 Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. J Natl Cancer Inst 2010 1.55
37 Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003 1.51
38 Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative. Am J Epidemiol 2008 1.48
39 Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009 1.46
40 Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2008 1.42
41 Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2011 1.37
42 Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol 2009 1.35
43 Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 2012 1.35
44 Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 2009 1.34
45 Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis. Cancer 2011 1.33
46 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002 1.32
47 Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006 1.31
48 Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev 2009 1.29
49 American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol 2008 1.29
50 Recreational physical activity, body mass index, and survival in women with colorectal cancer. Cancer Causes Control 2012 1.26
51 Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women's health initiative. Cancer Prev Res (Phila) 2014 1.26
52 A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2009 1.22
53 The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutr Cancer 2011 1.20
54 Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012 1.20
55 Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 2011 1.17
56 Management of bloody nipple discharge. Curr Treat Options Oncol 2002 1.12
57 Migraine history and breast cancer risk among postmenopausal women. J Clin Oncol 2010 1.11
58 Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2010 1.07
59 Aromatase inhibitor-associated arthralgias. J Clin Oncol 2009 1.06
60 Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings. J Fam Plann Reprod Health Care 2013 1.05
61 Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol 2013 1.03
62 The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. J Natl Cancer Inst 2011 1.03
63 Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer 2006 1.03
64 Interaction between body mass index and central adiposity and risk of incident cognitive impairment and dementia: results from the Women's Health Initiative Memory Study. J Am Geriatr Soc 2011 1.03
65 Adherence to oral endocrine therapy for breast cancer: a nursing perspective. Clin J Oncol Nurs 2008 1.02
66 Association between sleep and breast cancer incidence among postmenopausal women in the Women's Health Initiative. Sleep 2013 1.01
67 Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Cancer Prev Res (Phila) 2011 1.00
68 Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol 2012 1.00
69 Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res 2014 0.95
70 A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Res Treat 2008 0.95
71 Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014 0.93
72 Biological significance of interventions that change breast density. J Natl Cancer Inst 2003 0.92
73 Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. Cancer Epidemiol Biomarkers Prev 2012 0.92
74 Dietary cadmium exposure and risk of breast, endometrial, and ovarian cancer in the Women's Health Initiative. Environ Health Perspect 2014 0.91
75 Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 2005 0.91
76 Implementing a low-fat eating plan in the Women's Intervention Nutrition Study. J Am Diet Assoc 2009 0.91
77 Dietary vitamin D and calcium intake and mammographic density in postmenopausal women. Menopause 2010 0.90
78 Regression calibration in nutritional epidemiology: example of fat density and total energy in relationship to postmenopausal breast cancer. Am J Epidemiol 2013 0.90
79 Obesity and breast cancer outcome: adding to the evidence. J Clin Oncol 2011 0.90
80 Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative. Cancer Epidemiol Biomarkers Prev 2012 0.90
81 Vitamin D intake and lung cancer risk in the Women's Health Initiative. Am J Clin Nutr 2013 0.89
82 Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev 2011 0.89
83 Statins and breast cancer stage and mortality in the Women's Health Initiative. Cancer Causes Control 2015 0.89
84 Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial. Cancer Epidemiol Biomarkers Prev 2012 0.89
85 Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. J Natl Cancer Inst 2011 0.88
86 Dietary glycemic load, glycemic index, and carbohydrate and risk of breast cancer in the Women's Health Initiative. Nutr Cancer 2011 0.88
87 Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. Am J Clin Nutr 2009 0.88
88 Vitamin D and calcium supplementation and one-year change in mammographic density in the women's health initiative calcium and vitamin D trial. Cancer Epidemiol Biomarkers Prev 2012 0.88
89 Differences between estimated caloric requirements and self-reported caloric intake in the women's health initiative. Ann Epidemiol 2003 0.87
90 Caution in reinterpreting the Women's Health Initiative (WHI) Calcium and Vitamin D Trial breast cancer results. Am J Clin Nutr 2012 0.87
91 Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. Breast Cancer Res Treat 2011 0.87
92 Research staff turnover and participant adherence in the Women's Health Initiative. Control Clin Trials 2003 0.86
93 Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev 2008 0.86
94 Alcohol and folate consumption and risk of benign proliferative epithelial disorders of the breast. Int J Cancer 2007 0.86
95 Estrogen and progesterone-related gene variants and colorectal cancer risk in women. BMC Med Genet 2011 0.85
96 Women's health initiative view of estrogen avoidance and all-cause mortality. Am J Public Health 2013 0.84
97 Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. J Bone Miner Res 2013 0.84
98 Alcohol consumption and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2010 0.83
99 Obesity and early-stage breast cancer. J Clin Oncol 2005 0.83
100 Low-fat dietary pattern and risk of benign proliferative breast disease: a randomized, controlled dietary modification trial. Cancer Prev Res (Phila) 2008 0.83
101 The American Cancer Society guide for nutrition and physical activity for cancer survivors: a call to action for clinical investigators. CA Cancer J Clin 2003 0.83
102 Cigarette smoking and risk of benign proliferative epithelial disorders of the breast in the Women's Health Initiative. Cancer Causes Control 2007 0.82
103 Birth weight, breast cancer and the potential mediating hormonal environment. PLoS One 2012 0.82
104 The aromatase gene (CYP19A1) variants and circulating hepatocyte growth factor in postmenopausal women. PLoS One 2012 0.81
105 Diet and breast cancer recurrence. JAMA 2007 0.81
106 Utility of two cancer organization websites for a multiethnic, public hospital oncology population: comparative cross-sectional survey. J Med Internet Res 2005 0.80
107 Caution regarding 25-hydroxyvitamin D monitoring in women with breast cancer. J Clin Oncol 2009 0.80
108 Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. J Natl Cancer Inst 2008 0.80
109 Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. Cancer Causes Control 2011 0.79
110 Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. J Thorac Oncol 2015 0.78
111 Lifestyle and breast cancer risk: the way forward? J Clin Oncol 2010 0.78
112 Calcium plus vitamin D supplementation and joint symptoms in postmenopausal women in the women's health initiative randomized trial. J Acad Nutr Diet 2013 0.78
113 New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk. Arch Intern Med 2009 0.78
114 Current concepts in breast cancer chemoprevention. Pol Arch Med Wewn 2014 0.78
115 Progestins and recurrence in breast cancer survivors. J Natl Cancer Inst 2005 0.77
116 Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. Clin Breast Cancer 2009 0.77
117 Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER-Medicare data from 1993 to 2005. Cancer Med 2013 0.76
118 Investigating the association of lactation history and postmenopausal breast cancer risk in the Women's Health Initiative. Nutr Cancer 2013 0.76
119 Frequency of private spiritual activity and cardiovascular risk in postmenopausal women: the Women's Health Initiative. Ann Epidemiol 2013 0.76
120 Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. Breast Cancer Res Treat 2011 0.76
121 Re: "Invited commentary: personality as a causal factor in cancer risk and mortality--time to retire a hypothesis?". Am J Epidemiol 2011 0.75
122 Hormone therapy suspension and mammography in Women's Health Initiative clinical trials. Ann Intern Med 2010 0.75
123 Aromatase inhibitors and breast cancer treatment. JAMA 2006 0.75
124 Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009 0.75
125 Genetic variants in the MRPS30 region and postmenopausal breast cancer risk. Genome Med 2012 0.75
126 Re: Short-interval follow-up mammography: are we doing the right thing? J Natl Cancer Inst 2003 0.75
127 Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative. Menopause 2016 0.75
128 Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008 0.75
129 Tibolone in older postmenopausal women. N Engl J Med 2008 0.75
130 Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer. Prostaglandins Other Lipid Mediat 2011 0.75
131 Letrozole or tamoxifen in early breast cancer. N Engl J Med 2006 0.75
132 Toward optimal health: advances in breast cancer detection and management. Interview by Jodi R. Godfrey. J Womens Health (Larchmt) 2008 0.75
133 Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. Am J Epidemiol 2020 0.75
134 Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause 2017 0.75
135 Pre-empting breast cancer: where do we go from here? Womens Health (Lond Engl) 2008 0.75
136 Walking speed, physical activity, and breast cancer in postmenopausal women. Eur J Cancer Prev 2014 0.75
137 Recreational physical activity, anthropometric factors, and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. Cancer Causes Control 2010 0.75
138 Risk of breast, endometrial, colorectal, and renal cancers in postmenopausal women in association with a body shape index and other anthropometric measures. Cancer Causes Control 2014 0.75
139 How many protocols are deferred? One IRB's experience. IRB 1985 0.75
140 Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model. Med Decis Making 2002 0.75
141 Prentice et al. Respond to "Studying Co-Occurrence of Multiple Outcomes". Am J Epidemiol 2020 0.75
142 HT and breast cancer risk. Fertil Steril 2003 0.75
143 Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk. Menopause 2008 0.75
144 Emerging role for bisphosphonates in cancer management. Breast Dis 2011 0.75